RATIONALE: Genetic studies may help in understanding the genetic processes that cause some types of cancer. PURPOSE: Genetic trial to study certain genes of patients who have stage II or stage III colon cancer.
OBJECTIVES: * Determine the adverse prognostic significance of 8p allelic imbalance (AI) in patients with colon cancer. * Determine if patient prognosis is dependent on the region of 8p AI. * Perform fine mapping studies to further localize the putative tumor suppressor gene(s) on 8p. * Perform multicolor FISH to examine the role that 8p loss and 8q gain play in the prognosis of patients whose tumors exhibit 8p AI. OUTLINE: Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
Study Type
OBSERVATIONAL
Enrollment
598
overall survival
Time frame: Up to 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
St. Mary's/Duluth Clinic Health System
Duluth, Minnesota, United States
Tom Baker Cancer Center - Calgary
Calgary, Alberta, Canada
Lethbridge Cancer Clinic
Lethbridge, Alberta, Canada
Nanaimo Cancer Clinic
Nanaimo, British Columbia, Canada
British Columbia Cancer Agency - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
Prostate Centre at Vancouver General Hospital
Vancouver, British Columbia, Canada
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
St. Paul's Hospital - Vancouver
Vancouver, British Columbia, Canada
G. Steinhoff Clinical Research
Victoria, British Columbia, Canada
Moncton Hospital
Moncton, New Brunswick, Canada
...and 49 more locations